Skip to main navigation Skip to search Skip to main content

Brain- and heart-type fatty acid-binding proteins in the brain: Tissue distribution and clinical utility

  • Maurice M. A. L. Pelsers
  • , Thorsten Hanhoff
  • , Daniëlle van der Voort
  • , Baer Arts
  • , Maarten Peters
  • , Rudolf Ponds
  • , Adriaan Honig
  • , Wojtek Rudzinski
  • , Friedrich Spener
  • , Jelle R. de Kruijk
  • , Albert Twijnstra
  • , Wim T. Hermens
  • , Paul P. C. A. Menheere
  • , Jan F. C. Glatz
  • Maastricht University Medical Center and Cardiovascular Research Institute Maastricht (CARIM)
  • Maastricht University
  • Medical University of Białystok
  • University of Münster

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background: Detection of brain injury by serum markers is not a standard procedure in clinical practice, although several proteins, such as S100B, neuron-specific enolase (NSE), myelin basic protein, and glial fibrillary acidic protein, show promising results. We investigated the tissue distribution of brain- and heart-type fatty acid-binding proteins (B-FABP and H-FABP) in segments of the human brain and the potential of either protein to serve as plasma marker for diagnosis of brain injury. Methods: B-FABP and H-FABP were measured immunochemically in autopsy samples of the brain (n = 6) and in serum samples from (a) patients with mild traumatic brain injury (MTBI; n = 130) and (b) depressed patients undergoing bilateral electroconvulsive therapy (ECT; n = 14). The protein markers S100B and NSE were measured for comparison. Reference values of B-FABP and H-FABP were established in healthy individuals (n = 92). Results: The frontal, temporal, and occipital lobes, the striatum, the pons, and the cerebellum had different tissue concentrations of B-FABP and of H-FABP. B-FABP ranged from 0.8 μg/g wet weight in striatum tissue to 3.1 μg/g in frontal lobe. H-FABP was markedly higher, ranging from 16.2 μg/g wet weight in cerebellum tissue to 39.5 μg/g in pons. No B-FABP was detected in serum from healthy donors. H-FABP serum reference value was 6 μg/L. In the MTBI study, serum B-FABP was increased in 68% and H-FABP in 70% of patients compared with S100B (increased in 45%) and NSE (increased in 51% of patients). In ECT, serum B-FABP was increased in 6% of all samples (2 of 14 patients), whereas H-FABP was above its upper reference limit (6 μg/L) in 17% of all samples (8 of 14 patients), and S100B was above its upper reference limit (0.3 μg/L) in 0.4% of all samples. Conclusions: B-FABP and H-FABP patterns differ among brain tissues, with the highest concentrations in the frontal lobe and pons, respectively. However, in each part of the brain, the H-FABP concentration was at least 10 times higher than that of B-FABP. Patient studies indicate that B-FABP and H-FABP are more sensitive markers for minor brain injury than the currently used markers S100B and NSE. © 2004 American Association for Clinical Chemistry.
Original languageEnglish
Pages (from-to)1568-1575
JournalClinical chemistry
Volume50
Issue number9
DOIs
Publication statusPublished - Sept 2004
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Brain- and heart-type fatty acid-binding proteins in the brain: Tissue distribution and clinical utility'. Together they form a unique fingerprint.

Cite this